Skip to main content
. 2021 Jan 25;23(4):228. doi: 10.3892/mmr.2021.11867

Figure 1.

Figure 1.

Construction of a nintedanib-resistant colorectal cancer cell model. (A) IC50 value and inhibition rate of cells treated with different concentrations of nintedanib, as determined by Cell Counting Kit-8 assay. (B) Expression levels of miR-429 in CRC cell lines, as determined by reverse transcription-quantitative PCR. ***P<0.001 vs. SW480; ###P<0.001 vs. LoVo; P<0.05 vs. HCT116. miR-429, microRNA-429; -R, resistant to nintedanib.